http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018342909-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04c3dcc2e3046dc9ca3a8dbd5f5b41ce
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-549
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-59
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-88
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-56
filingDate 2018-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f7d730933880b15ced6ade786769872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_162c7076c9c0d716dc79d80f571e8002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78e36454e6a3513dee171d5e06cdb733
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da474cc7f798bb053e292f9afdb0217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37fd22b125a1c39217b5231fea0c4b38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2c69640a6dc8ffd6586fec79c895344
publicationDate 2020-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2018342909-A1
titleOfInvention Castration resistant prostate cancer
abstract The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.
priorityDate 2017-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467704152
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466984643
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466894151

Total number of triples: 35.